Integra LifeSciences Q1 2025: Adj EPS $0.41 vs $0.55 YoY; organic revenue down 3.5%

INTEGRA LIFESCIENCES HOLDINGS CORP

2025-Q1 EPS reported -$0.33 revenue$382,653,000

Revenue of $382.7M up 3.7% reported but down 3.5% organic; GAAP net loss $(0.33)/share vs $(0.04).
Adjusted EPS $0.41 vs $0.55 prior year; adjusted gross margin 62.2% vs 64.4%.
Codman Specialty Surgical organic revenue -1.1%; Tissue Technologies organic -9.1%.
Full-year 2025 revenue reaffirmed $1.65B-$1.715B; adj EPS guidance reduced to $2.19-$2.29 (incl $(0.22) tariff impact).
Q2 2025 guidance: revenue $390M-$400M, adj EPS $0.40-$0.45; operating cash flow negative $(11.3)M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.